Latent Autoimmune Diabetes in Adults (LADA)

IWBCA
Feb 13
11 min read

Latent autoimmune diabetes in adults (LADA), sometimes called Type 1.5 diabetes, is an autoimmune form of diabetes that appears in adulthood and progresses more slowly than classic Type 1. Because early features resemble Type 2 diabetes, many people initially receive a Type 2 diagnosis before antibody testing and treatment response reveal that LADA is present.

Overview

What is latent autoimmune diabetes in adults (LADA)?

Latent autoimmune diabetes in adults is an autoimmune form of diabetes that appears in adulthood and is known by several names. It is most often called LADA, but may also be described as “Type 1.5 diabetes,” “adult-onset autoimmune diabetes,” or “slowly progressive Type 1 diabetes.” All of these labels refer to the same underlying process: the immune system targets and gradually destroys the pancreatic beta cells the produce insulin. As in Type 1 diabetes, autoantibodies recognize beta-cell structures and interfere with their function and survival. Unlike classic childhood-onset Type 1 diabetes, however, this destruction usually progresses more slowly and presents later in life, with milder symptoms and only partial insulin deficiency at the start.

Early in the course of LADA, many people still produce enough of their own insulin to keep blood sugar near target using lifestyle measures or tablets typically prescribed for Type 2 diabetes. Because of this, a large proportion of adults with LADA receive an initial diagnosis of Type 2, particularly when they are in their 30s, 40s, or 50s and do not appear acutely unwell. Over time, as the autoimmune process progresses, beta-cell function declines, oral medications lose efficacy, and the need for insulin replacement becomes evident. Antibody testing and measurement of C-peptide, which reflects the amount of insulin the pancreas is still producing, help distinguish LADA from Type 2 diabetes and guide the timing of transition to an insulin-based regimen.

Clinicians are more likely to suspect LADA when an adult labeled with Type 2 diabetes is not overweight, has a personal or family history of autoimmune disease, or requires insulin much sooner than expected despite structured lifestyle changes and appropriate tablets. Most diagnoses occur between ages 30 and 50, but LADA can present earlier or later, which is why the possibility of adult-onset autoimmune diabetes should be considered whenever the clinical course does not fit typical Type 2 patterns.

Prevalence

How common is LADA?

LADA is more common than many people realize. Studies suggest that roughly 4% to 12% of adults who are told they have Type 2 diabetes actually have an autoimmune process consistent with LADA when they are tested for pancreatic autoantibodies. Given that hundreds of millions of adults worldwide carry a Type 2 label, this percentage translates to several million individuals with LADA.

Because LADA is frequently misclassified at the start, its true prevalence is likely underestimated in routine practice. Awareness among clinicians and patients, along with thoughtful use of antibody and C-peptide testing in adults whose course does not fit typical Type 2 patterns, increases the likelihood that LADA is recognized and treated in a manner that preserves remaining beta-cell function for as long as possible.

Symptoms and Causes

What are the symptoms of LADA diabetes?

The symptoms of latent autoimmune diabetes in adults (LADA) overlap with those of other forms of diabetes, but the pace is often slower and easier to underestimate. Many people feel generally “off” for months before anyone checks glucose or considers an autoimmune cause.

Being Very Thirsty (Polydipsia). People with LADA often notice a persistent, difficult-to-quench thirst. You may find yourself carrying water everywhere, waking at night to drink, or feeling that your mouth is dry even after large amounts of fluid. This happens because elevated blood sugar pulls water out through the kidneys, so your body drives you to drink in an effort to replace what you are losing.

Needing To Urinate More Often: Frequent urination, including multiple nocturnal awakenings, is a core symptom. When blood glucose is high, the kidneys excrete excess sugar into the urine, and water follows. Each trip to the bathroom can involve a large volume of pale urine. Over time, this leads to fatigue, sleep disruption, and a sense that daily life is organized around access to bathrooms.

Losing Weight Unexpectedly: Unintentional weight loss, even when appetite is normal or increased, is a key clue. As insulin levels fall and cells cannot use glucose effectively, the body turns to fat and muscle as fuel. This can cause noticeable weight loss over weeks to months, looser clothing, and changes in body composition even before a formal diagnosis is made.

Blurred Vision: Fluctuating blood sugar changes the fluid balance in the lens of the eye. People with LADA may notice periods when their vision becomes hazy, objects are harder to focus on, or prescription glasses seem to stop working reliably from one day to the next. These changes often improve when glucose is better controlled, but they are a signal that blood glucose has been elevated.

Fatigue: Many individuals report a deep, persistent tiredness that appears disproportionate to their schedule. When cells cannot access glucose efficiently, everyday tasks require more effort, recovery after activity is slower, and concentration may suffer. This fatigue can easily be misattributed to stress or aging if blood sugar is not checked.

Itchy, Dry Skin: High blood sugar promotes fluid loss and can dry the skin. People with LADA may develop generalized itching, especially on the lower legs and trunk, and notice that small scratches or rashes seem more irritated than usual. Dryness also increases the risk of skin infections, which is another indication that glucose may be elevated.

Causes

What causes LADA?

LADA is driven by an autoimmune process in which the immune system mistakenly targets the insulin-producing beta cells in the pancreas. Over time, antibodies and immune cells damage beta cells, reducing their insulin production. As insulin output declines, blood sugar rises, and the classic symptoms of diabetes appear.

In this respect, LADA resembles Type 1 diabetes, where an autoimmune attack leads to absolute insulin deficiency. The difference is that in LADA, the process is usually slower and more gradual. Many people still make a meaningful amount of their own insulin at the time of diagnosis, so they may respond at first to lifestyle changes or tablets commonly used for Type 2 diabetes. As months and years pass, beta-cell function continues to fall until insulin injections become necessary to maintain safe glucose levels.

Because the onset is gradual and occurs in adulthood, LADA often fits the pattern clinicians expect from Type 2 diabetes at first glance, especially if there is no obvious illness at presentation. This is why antibody testing and C-peptide measurement (a marker of how much insulin your body still makes) are useful when the course does not match typical Type 2 expectations.

Triggers

What are the most common triggers of LADA diabetes?

Current evidence suggests that LADA does not have a single external “trigger” that can be identified in most people. The autoimmune process develops when the immune system loses tolerance to beta-cell antigens and mounts an immune response against them. This shift occurs outside a person’s control and is influenced by genetic susceptibility and, likely, a combination of environmental exposures that are not yet fully understood.

In early LADA, the pancreas may still release sufficient insulin to maintain blood glucose just above normal, so symptoms are absent or mild. During this phase, standard blood tests may reveal borderline abnormalities that are easy to overlook, and the condition may remain unnoticed until beta-cell loss reaches a point at which the body can no longer compensate.

Risk Factors

What are the risk factors for LADA?

LADA has a strong autoimmune and genetic component. It is more likely to occur in people who have a personal or family history of autoimmune conditions, such as Type 1 diabetes, autoimmune thyroid disease, celiac disease, or vitiligo. Having a biological parent or grandparent with LADA or early-onset insulin-dependent diabetes increases the chance of carrying genes that predispose to this form of autoimmunity.

Environmental and lifestyle factors may also influence the timing and presentation of LADA. Excess body weight, particularly central obesity, can exacerbate insulin resistance on top of emerging insulin deficiency, leading to higher blood glucose levels sooner and more sharply. Some infections and stressors are being studied as possible contributors to immune dysregulation, although no single exposure has been proven to cause LADA on its own. Overall, risk reflects the interaction between inherited susceptibility and the metabolic environment in which the immune system and beta cells operate.

Complications

What are the complications of LADA?

The most important complication of LADA in the early and middle stages is misclassification. When LADA is treated as if it were typical Type 2 diabetes for too long, people may not receive insulin when they need it, and blood sugar can remain elevated despite best efforts with lifestyle changes and oral medications. This prolonged hyperglycemia increases the risk of eye disease, kidney disease, nerve damage, and cardiovascular complications in the same way it does in other forms of diabetes.

As beta-cell function continues to decline, people with LADA become vulnerable to acute complications that reflect absolute or near-absolute insulin deficiency. Diabetes-related ketoacidosis (DKA) is the most serious of these. DKA develops when there is not enough insulin for cells to use glucose, so the body breaks down fat rapidly for energy. This produces ketones and acids that accumulate in the bloodstream, leading to dehydration, abdominal pain, vomiting, rapid breathing, and, without prompt treatment, confusion, coma, or death. DKA can be the first presentation of LADA in some adults who were previously thought to have Type 2 diabetes when their remaining beta-cell function suddenly fails.

Over the longer term, if LADA remains under-treated or glucose control is unstable, the spectrum of complications is similar to other forms of diabetes: damage to small vessels in the eyes and kidneys, neuropathy affecting sensation and autonomic function, increased risk of heart attack and stroke, and greater susceptibility to infections. Correctly identifying LADA and moving to an insulin-based regimen when indicated are key steps in reducing these risks and preserving health.

Diagnosis and Tests

How is LADA diabetes diagnosed?

LADA most often comes to light in adults who are first labeled as having Type 2 diabetes because they present in midlife, are not acutely ill, and may initially respond to tablets and lifestyle changes. Suspicion for LADA increases when blood sugar remains difficult to control despite appropriate oral medications, when insulin is needed unusually early after a “Type 2” diagnosis, or when the person has a personal or family history of autoimmune disease.

Diagnosis relies on combining clinical clues with specific blood tests:

GAD Antibody Testing: A glutamic acid decarboxylase (GAD) antibody test looks for autoantibodies directed against the GAD enzyme in the pancreatic beta cell. The presence of GAD antibodies in an adult with diabetes indicates an autoimmune process affecting the pancreas. In this setting, a positive GAD test makes LADA much more likely than typical Type 2 diabetes. Some people with LADA also have other islet autoantibodies, such as antibodies to IA-2 or ZnT8, which further support an autoimmune cause. These tests do not determine the severity of diabetes, but they help clarify why insulin is becoming necessary.

C-Peptide Testing: A C-peptide test measures how much C-peptide is in the blood, which reflects how much insulin the pancreas is still making. In early LADA, C-peptide may be in the low-normal range and then declines over time as beta cells are lost. Low or declining C-peptide levels in an adult with positive GAD antibodies and “Type 2” features point strongly to LADA rather than pure insulin resistance. Providers may repeat C-peptide measurements to track beta-cell function and time the transition to full insulin replacement.

In practice, clinicians integrate age at onset, body weight, presence of other autoimmune conditions, treatment response, antibody results, and C-peptide levels. This pattern-based approach distinguishes LADA from classic Type 1 diabetes, which typically presents in childhood, and from Type 2 diabetes, which is driven primarily by insulin resistance.

Management and Treatment

What is the treatment for LADA diabetes?

Treating LADA requires planning for a moving target. Early in the course, many people respond to lifestyle measures and tablets that are commonly used in Type 2 diabetes. As autoimmune destruction of beta cells progresses, the body’s own insulin production falls, and these approaches become less effective. Over time, insulin therapy becomes central rather than optional.

In the early stages, a healthcare provider may recommend:

Nutrition strategies that moderate carbohydrate intake and distribute it evenly throughout the day
Regular physical activity can improve insulin sensitivity
Metformin or other non-insulin medications when insulin resistance is present

These steps can improve glycemic control while the pancreas continues to produce meaningful insulin. However, as C-peptide levels decline and blood glucose rises, the focus shifts toward insulin replacement.

Many experts favor starting insulin earlier in LADA than in typical Type 2 diabetes. The reasoning is that gentle, timely use of insulin can reduce the workload on stressed beta cells and may help preserve remaining function for longer. Others introduce insulin when blood sugar and A1c remain above target despite best efforts with lifestyle and tablets. In both approaches, the long-term destination is similar: a regimen that includes basal insulin and, when needed, mealtime doses.

There is no single universal schedule for initiating insulin or for choosing an insulin regimen. Doses and timing are tailored to body weight, residual insulin production, daily routines, and the risk of hypoglycemia. People with LADA require ongoing education on insulin use, glucose monitoring, sick-day rules, and recognition of hypoglycemia. Regular review of glucose data with the care team allows adjustments as the disease evolves and beta-cell function changes.

Outlook and Prognosis

What can I expect if I have this condition?

LADA is a chronic autoimmune condition without a cure, but it is manageable. Once the diagnosis is clear and an insulin-based regimen is in place, many people find that their blood sugar becomes easier to control than it was when they were being treated as if they had Type 2 diabetes alone. The goal is not only to lower glucose numbers in the short term but also to reduce the risk of long-term complications affecting the eyes, kidneys, nerves, heart, and blood vessels.

Life Expectancy

What is the life expectancy of someone with LADA diabetes?

Life expectancy in LADA depends on overall diabetes control and the presence of other risk factors, not on the label itself. Having LADA does not automatically shorten lifespan. The main threat comes from long periods of poorly controlled blood sugar, which raises the likelihood of cardiovascular disease, kidney disease, neuropathy, and other complications that can be life-limiting.

People with LADA who receive a timely diagnosis, move to appropriate insulin therapy, and manage blood pressure, lipids, and lifestyle factors can often achieve outcomes similar to those seen in well-managed Type 1 or Type 2 diabetes. Regular follow-up, screening for complications, and attention to mental health make a measurable difference in quality and length of life.

Prevention

Can you prevent LADA diabetes?

There is currently no known way to prevent LADA, because it arises from an autoimmune process that cannot yet be reliably predicted or stopped. Unlike Type 2 diabetes, in which weight, physical activity, and diet have a substantial influence on risk, LADA largely reflects genetic susceptibility and immune regulation.

What can be influenced is the timing of recognition and the prevention of complications. Early diagnosis, appropriate antibody and C-peptide testing when the course of “Type 2” diabetes does not fit expectations, and earlier use of insulin when needed all help limit the years spent with uncontrolled blood sugar. This, in turn, reduces the likelihood of long-term organ damage.

Life After Diagnosis

How can I take the best care of myself?

Living well with LADA centers on learning and practicing daily diabetes self-management skills. This includes understanding how to use insulin, how food and activity affect your blood sugar, how to monitor glucose accurately, and how to respond when readings are too high or too low. Because LADA is often misdiagnosed, many people reach the correct diagnosis feeling frustrated or discouraged, especially if they have been told that high readings were due to “noncompliance” rather than an underlying autoimmune process. Recognizing that the biology has changed, not that you have failed, is an important step.

Once you have a confirmed LADA diagnosis, it is important to:

Follow the treatment plan you develop with your healthcare provider, including insulin and any non-insulin medications
Monitor your blood sugar as recommended, using a meter or continuous glucose monitor when available
Attend all follow-up appointments, so your team can track changes in beta-cell function, adjust insulin doses, and screen for early complications
Ask for support with nutrition, physical activity, mental health, and problem-solving around work, travel, and illness

These steps help stabilize blood sugar and reduce day-to-day uncertainty.

Seeking Care

When should I see my healthcare provider?

You should contact a healthcare provider if you notice symptoms of diabetes, such as excessive thirst, frequent urination, unexplained weight loss, blurred vision, or fatigue. Sharing a complete health history, including personal and family autoimmune conditions, helps your provider decide when to test for LADA instead of assuming Type 2 diabetes.

If you have already been told you have Type 2 diabetes and your blood sugar remains high despite consistent use of medications and lifestyle changes, or if you need insulin very soon after diagnosis, it is reasonable to ask about testing for LADA. Re-evaluating the diagnosis can change the treatment strategy and give you access to the tools you need to manage your condition more effectively.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.